🚀 VC round data is live in beta, check it out!
Cheezheng Tibetan Medicine Valuation Multiples
Discover revenue and EBITDA valuation multiples for Cheezheng Tibetan Medicine and similar public comparables like Sionna Therapeutics, Trevi Therapeutics, Lotus Pharmaceutical, AnaptysBio and more.
Cheezheng Tibetan Medicine Overview
About Cheezheng Tibetan Medicine
Tibet Cheezheng Tibetan Medicine Co Ltd is Tibetan medicine manufacturer. It is mainly engaged in the research, development, production, and sales of Tibetan medicines. The company's products include medicines such as emplastrum, ointments, granules, pills, and powders.
Founded
1997
HQ
Employees
1.2K
Website
Sectors
Financials (FY)
EV
$2B
Cheezheng Tibetan Medicine Financials
Cheezheng Tibetan Medicine reported last fiscal year revenue of $343M and EBITDA of $124M.
In the same fiscal year, Cheezheng Tibetan Medicine generated $281M in gross profit, $124M in EBITDA, and $85M in net income.
Cheezheng Tibetan Medicine P&L
In the most recent fiscal year, Cheezheng Tibetan Medicine reported revenue of $343M and EBITDA of $124M.
Cheezheng Tibetan Medicine expects next 12-month revenue of XXX and NTM EBITDA of XXX
| LTM | NTM | Last FY | FY 2026 | FY 2027 | FY 2028 | |
|---|---|---|---|---|---|---|
| Revenue | — | XXX | $343M | XXX | XXX | XXX |
| Gross Profit | — | XXX | $281M | XXX | XXX | XXX |
| Gross Margin | — | XXX | 82% | XXX | XXX | XXX |
| EBITDA | — | XXX | $124M | XXX | XXX | XXX |
| EBITDA Margin | — | XXX | 36% | XXX | XXX | XXX |
| EBIT Margin | — | XXX | 26% | XXX | XXX | XXX |
| Net Profit | — | XXX | $85M | XXX | XXX | XXX |
| Net Margin | — | XXX | 25% | XXX | XXX | XXX |
| Net Debt | — | — | $208M | XXX | XXX | XXX |
Financial data powered by Morningstar, Inc.
Cheezheng Tibetan Medicine Stock Performance
Cheezheng Tibetan Medicine has current market cap of $2B, and enterprise value of $2B.
Market Cap Evolution
Cheezheng Tibetan Medicine's stock price is $3.42.
| EV | Market Cap | Price 1D | Price 1M | Price 3M | Price 12M | EPS |
|---|---|---|---|---|---|---|
| $2B | $2B | -0.6% | XXX | XXX | XXX | $0.15 |
Benchmark Trading Valuation Multiples by Industry
Sign up to access valuation multiples like growth-adjusted P/E, Rule of 40, next 12-month EV/Revenue, EBITDA multiples by industry, consensus analyst estimates and many more.
Start Free TrialCheezheng Tibetan Medicine Valuation Multiples
Cheezheng Tibetan Medicine trades at 4.8x EV/Revenue multiple, and 13.4x EV/EBITDA.
Cheezheng Tibetan Medicine Financial Valuation Multiples
As of April 18, 2026, Cheezheng Tibetan Medicine has market cap of $2B and EV of $2B.
Equity research analysts estimate Cheezheng Tibetan Medicine's 2025E EV/Revenue multiple at XXX and 2025E EV/EBITDA multiple at XXX
Cheezheng Tibetan Medicine has a P/E ratio of 22.9x.
| LTM | NTM | Last FY | FY 2026 | FY 2027 | FY 2028 | |
|---|---|---|---|---|---|---|
| Market cap (current) | $2B | XXX | $2B | XXX | XXX | XXX |
| EV (current) | $2B | XXX | $2B | XXX | XXX | XXX |
| EV/Revenue | — | XXX | 4.8x | XXX | XXX | XXX |
| EV/EBITDA | — | XXX | 13.4x | XXX | XXX | XXX |
| EV/EBIT | — | XXX | 18.5x | XXX | XXX | XXX |
| EV/Gross Profit | — | XXX | 5.9x | XXX | XXX | XXX |
| P/E | — | XXX | 22.9x | XXX | XXX | XXX |
| EV/FCF | — | XXX | 56.1x | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Verified Cheezheng Tibetan Medicine Valuation Multiples
Access all public comps and forward-looking valuation multiples like EV/Revenue in 2027, based on consensus analyst estimates. Powered by FactSet and Morningstar.
Cheezheng Tibetan Medicine Margins & Growth Rates
Cheezheng Tibetan Medicine's revenue in the last fiscal year grew by 14%.
Cheezheng Tibetan Medicine's revenue per employee in the last FY averaged $0.3M, while opex per employee averaged $0.2M for the same period.
Cheezheng Tibetan Medicine Operational Valuation Multiples
| LTM | NTM | Last FY | FY 2026 | FY 2027 | FY 2028 | |
|---|---|---|---|---|---|---|
| Revenue Growth | — | XXX | 14% | XXX | XXX | XXX |
| EBITDA Margin | — | XXX | 36% | XXX | XXX | XXX |
| EBITDA Growth | — | XXX | 5% | XXX | XXX | XXX |
| Revenue per Employee | — | XXX | $0.3M | XXX | XXX | XXX |
| Opex per Employee | — | XXX | $0.2M | XXX | XXX | XXX |
| S&M Expenses to Revenue | — | XXX | 34% | XXX | XXX | XXX |
| G&A Expenses to Revenue | — | XXX | 2% | XXX | XXX | XXX |
| R&D Expenses to Revenue | — | XXX | 3% | XXX | XXX | XXX |
| Opex to Revenue | — | XXX | 56% | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Cheezheng Tibetan Medicine Public Comps
See public comps and valuation multiples for other Biopharmaceuticals comps.
| EV/Revenue | EV/EBITDA | |||||
|---|---|---|---|---|---|---|
| LTM | 2026E | 2027E | LTM | 2026E | 2027E | |
| Cheezheng Tibetan Medicine | XXX | XXX | XXX | XXX | XXX | XXX |
| Sionna Therapeutics | XXX | XXX | XXX | XXX | XXX | XXX |
| Trevi Therapeutics | XXX | XXX | XXX | XXX | XXX | XXX |
| Lotus Pharmaceutical | XXX | XXX | XXX | XXX | XXX | XXX |
| AnaptysBio | XXX | XXX | XXX | XXX | XXX | XXX |
| Hugel | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc.
Cheezheng Tibetan Medicine M&A Activity
Cheezheng Tibetan Medicine acquired XXX companies to date.
Last acquisition by Cheezheng Tibetan Medicine was on XXXXXXXX, XXXXX. Cheezheng Tibetan Medicine acquired XXXXXXXX for XXX (EV/Revenue multiple of XXX).
Latest Acquisitions by Cheezheng Tibetan Medicine
| Acquired Company | Valuation | EV/Revenue | EV/EBITDA |
|---|---|---|---|
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
Get Verified M&A Valuation Multiples
Sign up to see revenue and EBITDA valuation multiples for 150K+ M&A deals.
Start Free TrialCheezheng Tibetan Medicine Investment Activity
Cheezheng Tibetan Medicine invested in XXX companies to date.
Cheezheng Tibetan Medicine made its latest investment on XXXXXXXX, XXXXX. Cheezheng Tibetan Medicine invested in XXXXXXXX for XXX (EV/Revenue multiple of XXX).
Latest Investments by Cheezheng Tibetan Medicine
| Company | Valuation | EV/Revenue | EV/EBITDA |
|---|---|---|---|
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
Benchmark 350K+ Funding Rounds and Disclosed VC Valuation Multiples
Sign up to see data on 350K+ funding rounds and disclosed revenue and EBITDA valuation multiples, from seed, through growth stage, to pre-IPO.
Start Free TrialAbout Cheezheng Tibetan Medicine
| When was Cheezheng Tibetan Medicine founded? | Cheezheng Tibetan Medicine was founded in 1997. |
| Where is Cheezheng Tibetan Medicine headquartered? | Cheezheng Tibetan Medicine is headquartered in China. |
| How many employees does Cheezheng Tibetan Medicine have? | As of today, Cheezheng Tibetan Medicine has over 1K employees. |
| Is Cheezheng Tibetan Medicine publicly listed? | Yes, Cheezheng Tibetan Medicine is a public company listed on Shenzhen Stock Exchange. |
| What is the stock symbol of Cheezheng Tibetan Medicine? | Cheezheng Tibetan Medicine trades under 002287 ticker. |
| When did Cheezheng Tibetan Medicine go public? | Cheezheng Tibetan Medicine went public in 2009. |
| Who are competitors of Cheezheng Tibetan Medicine? | Cheezheng Tibetan Medicine main competitors are Sionna Therapeutics, Trevi Therapeutics, Lotus Pharmaceutical, AnaptysBio. |
| What is the current market cap of Cheezheng Tibetan Medicine? | Cheezheng Tibetan Medicine's current market cap is $2B. |
| What is the current revenue of Cheezheng Tibetan Medicine? | Cheezheng Tibetan Medicine's last fiscal year revenue is $343M. |
| What is the current EV/Revenue multiple of Cheezheng Tibetan Medicine? | Current revenue multiple of Cheezheng Tibetan Medicine is 4.8x. |
| Is Cheezheng Tibetan Medicine profitable? | No, Cheezheng Tibetan Medicine is not profitable. |
Start Your
Free Trial Today
Try Multiples for free for 3 days. Got questions or need a demo? Schedule a call with us below.